Journal of Clinical Pediatrics >
Pulmonary manifestation associated with rheumatic diseases in children
Received date: 2022-07-04
Online published: 2022-10-12
Childhood rheumatic diseases are a group of autoimmune diseases mainly manifested by multi-system damage. Pulmonary involvement is rare in pediatric rheumatic diseases. The symptoms of pulmonary involvement are often insidious, and there may be no obvious clinical manifestations or only mild symptoms in the early stage, leading to the diagnostic difficulties, which is one of the main factors affecting the mortality of children with rheumatic diseases. Therefore, understanding the specific manifestations of pulmonary involvement in different children with rheumatic diseases, early screening, early identification and early intervention for high-risk children can better improve the prognosis and life quality of children.
Key words: rheumatic disease; autoimmune disease; pulmonary manifestation; childhood
Jieyuan CUI . Pulmonary manifestation associated with rheumatic diseases in children[J]. Journal of Clinical Pediatrics, 2022 , 40(10) : 726 -732 . DOI: 10.12372/jcp.2022.22e0923
[1] | Bundhun PK, Kumari A, Huang F. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96: e8086. |
[2] | Veiga CS, Coutinho DS, Nakaie CMA, et al. Subclinical pulmonary abnormalities in childhood-onset systemic lupus erythematosus patients[J]. Lupus, 2016, 25: 645-651. |
[3] | Torre O, Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus[J]. Presse Medicale Paris Fr, 2011, 40 (1 Pt 2): e19-e29. |
[4] | Carmier D, Marchand-Adam S, Diot P, et al. Respiratory involvement in systemic lupus erythematosus[J]. Rev Mal Respir, 2010, 27: e66-e78. |
[5] | Cutolo M, Melsens K, Wijnant S, et al. Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal[J]. Autoimmun Rev, 2018, 17: 344-352. |
[6] | Anuardo P, Verdier M, Gormezano NWS, et al. Subclinical pulmonary hypertension in childhood systemic lupus erythematosus associated with minor disease manifestations[J]. Pediatr Cardiol, 2017, 38: 234-239. |
[7] | Araujo DB, Borba EF, Silva CA, et al. Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus[J]. Lupus, 2012, 21: 872-877. |
[8] | Mira-Avendano IC, Abril A. Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease[J]. Rheum Dis Clin North Am, 2015, 41: 263-277. |
[9] | Campos LMA, Kiss MH, D’Amico EA, et al. Anti-phospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus[J]. Lupus, 2003, 12: 820-826. |
[10] | Nigrovic PA. Storm warning: lung disease in systemic juvenile idiopathic arthritis[J]. Arthritis Rheumatol Hoboken NJ, 2019, 71: 1773-1775. |
[11] | Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study[J]. Rheumatol Oxf Engl, 2014, 53: 1676-1682. |
[12] | Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival[J]. Respir Med, 2017, 126: 100-104. |
[13] | Mohd Noor N, Mohd Shahrir MS, Shahid MS, et al. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease[J]. Int J Rheum Dis, 2009, 12: 136-144. |
[14] | Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis[J]. Arthritis Care Res, 2013, 65: 745-752. |
[15] | Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis[J]. Ann Rheum Dis, 2019, 78: 1722-1731. |
[16] | Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate[J]. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG, 2001, 18: 243-252. |
[17] | 侯俊, 闫淯淳, 苏改秀, 等. 抗黑色素瘤分化相关基因蛋白5抗体与幼年皮肌炎间质性肺病严重程度的关系[J]. 中华医学杂志, 2021, 101(33): 2606-2610. |
[18] | Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial[J]. Lancet Respir Med, 2016, 4: 708-719. |
[19] | Robles-Perez A, Dorca J, Castellví I, et al. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data[J]. Rheumatol Int, 2020, 40: 719-726. |
[20] | Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76: 1327-1339. |
[21] | Valeur NS, Stevens AM, Ferguson MR, et al. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis[J]. AJR Am J Roentgenol, 2015, 204: 408-422. |
[22] | Lin Y, Yi Q, Cheng D. Rapid progressive interstitial lung disease as initial manifestation of primary Sjögren’s syndrome: a case report[J]. Int J Clin Exp Med, 2014, 7: 5904-5908. |
[23] | Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings[J]. Arthritis Rheum, 1999, 42: 899-909. |
[24] | Hetlevik SO, Flatø B, Rygg M, et al. Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study[J]. Ann Rheum Dis, 2017, 76: 159-165. |
[25] | Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension[J]. Scand J Immunol, 2006, 64: 69-76. |
/
〈 |
|
〉 |